NR3C2 and acute myocardial infarction: However, TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist) in HFpEF [68, 69] and ALBATROSS trial (Aldosterone Lethal effects Blocked in Acute Myocardial Infarction Treated with or without Reperfusion to improve Outcome and Survival at Six months follow-up) in patients with acute myocardial infarction, 92% of whom presented without heart failure [70], both trials failed to support these findings about the effectiveness of MR antagonist in reducing cardiovascular mortality and heart failure hospitalizations (Table 1).